For the readers interested in the stock health of Bicycle Therapeutics plc (BCYC). It is currently valued at $25.50. When the transactions were called off in the previous session, Stock hit the highs of $26.35, after setting-off with the price of $23.00. Company’s stock value dipped to $23.00 during the trading on the day. When the trading was stopped its value was $19.85.
Recently in News on January 14, 2021, Bicycle Therapeutics Announces Pipeline Progress Update. – BT1718 progressing in Cancer Research UK sponsored Phase IIa clinical trial. You can read further details here
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Bicycle Therapeutics plc had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $26.35 on 01/14/21, with the lowest value was $18.00 for the same time period, recorded on 01/04/21.
Bicycle Therapeutics plc (BCYC) full year performance was 131.19%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Bicycle Therapeutics plc shares are logging 12.29% during the 52-week period from high price, and 148.54% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $10.26 and $22.71.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1076217 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Bicycle Therapeutics plc (BCYC) recorded performance in the market was 42.06%, having the revenues showcasing 34.71% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 546.47M, as it employees total of 72 workers.
Bicycle Therapeutics plc (BCYC) in the eye of market guru’s
During the last month, 7 analysts gave the Bicycle Therapeutics plc a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 19.20, with a change in the price was noted +7.22. In a similar fashion, Bicycle Therapeutics plc posted a movement of +39.50% for the period of last 100 days, recording 80,483 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for BCYC is recording 0.13 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.13.
Bicycle Therapeutics plc (BCYC): Stocks Technical analysis and Trends
Raw Stochastic average of Bicycle Therapeutics plc in the period of last 50 days is set at 89.88%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 89.88%. In the last 20 days, the company’s Stochastic %K was 71.36% and its Stochastic %D was recorded 65.12%.
If we look into the earlier routines of Bicycle Therapeutics plc, multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 42.06%. Additionally, trading for the stock in the period of the last six months notably improved by 36.51%, alongside a boost of 131.19% for the period of the last 12 months. The shares increased approximately by 28.92% in the 7-day charts and went down by 33.79% in the period of the last 30 days. Common stock shares were driven by 34.71% during last recorded quarter.